It also said its net profit rose 14% to RON20.27 million in the first nine months, from RON17.7 million in the same period in 2013.
The company’s pretax profit of RON23.6 million in the mentioned period was 24% higher than in January-September 2013.
Antibiotice’s exports in the first nine months reached $18.36 million, slightly up from $18.04 million in the same period in 2013.
Antibiotice ranks 11th on the Romanian market, with a 2.6% share.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53.02% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 12.02% stake.
On the Bucharest Stock Exchange Friday, Antibiotice traded at RON0.5660 a share.